RecruitingNot ApplicableNCT04984291

Zimmer Biomet Shoulder Arthroplasty PMCF

Zimmer Biomet Shoulder Arthroplasty Long-term Post Market Clinical Follow-up Study


Sponsor

Zimmer Biomet

Enrollment

584 participants

Start Date

Jul 28, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

The objectives of this study are to confirm the safety, performance, and clinical benefits of Zimmer Biomet Shoulder Arthroplasty Systems and its instrumentation in primary or revision shoulder arthroplasty. These objectives will be assessed using standard scoring systems, radiographic evidence, and adverse event records. Safety of the system will be assessed by monitoring the frequency an incidence of adverse events.


Eligibility

Min Age: 20 Years

Inclusion Criteria14

  • Patient must be 20 years of age or older.
  • Patient must be anatomically and structurally suited to receive shoulder arthroplasty implants.
  • Patient is a candidate for shoulder arthroplasty due to one or more of the following:
  • Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis.
  • Rheumatoid arthritis.
  • Correction of functional deformity.
  • Fractures of the proximal humerus, where other methods of treatment are deemed inadequate.
  • Difficult clinical management problems, where other methods of treatment may not be suitable or may be inadequate.
  • Patient must be able and willing to complete the protocol required follow-up.
  • Patient must be able and willing to sign the IRB/EC approved informed consent.
  • Patient has grossly deficient rotator, (for reverse application)
  • With severe arthropathy and/or
  • Previously failed shoulder joint replacement
  • Patient must have functional deltoid muscle (for reverse application)

Exclusion Criteria15

  • Patient is unwilling or unable to give consent or to comply with the follow-up program.
  • Patient has any condition which would in the judgement of the Investigator, place the patient at undue risk or interfere with the study.
  • Patient is known to be pregnant or breastfeeding.
  • Patient is a vulnerable subject (prisoner, mentally incompetent or unable to understand what participation to the study entails, a known alcohol or drug abuser, and/or anticipated to be non-compliant).
  • Patient is uncooperative or patient with neurologic disorders who is incapable or unwilling to follow directions.
  • Patient has any sign of infection affecting the shoulder joint or in its proximity which may spread to the implant site.
  • Patient has rapid joint destruction, marked bone loss, or bone resorption apparent on roentgenogram.
  • Patient has any neuromuscular disease compromising the affected limb that would render the procedure unjustifiable.
  • Patient presents with osteoporosis, which in the opinion of the Investigator, may limit the subject's ability to support total shoulder arthroplasty using the study device.
  • Patient has osteomalacia.
  • Patient has a metabolic disorder that may impair bone formation.
  • Patient has deficient rotator cuff.
  • Patient presents with significant injury to the upper brachial plexus.
  • Patient has paralysis of the axillary nerve.
  • Patient has non-functional deltoid or external rotator muscles.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEAlliance Glenoid

Alliance Glenoid used in Primary or Revision Total Shoulder Arthroplasty

DEVICEIdentity Stem

Identity Shoulder System is intended to be used in anatomic total shoulder arthroplasty, shoulder hemi-arthroplasty, or total reverse shoulder arthroplasty in both Primary or Revision Total Shoulder Arthroplasty


Locations(17)

Hoag Orthopedic Institute

Irvine, California, United States

Panorama Orthopaedic and Spine Center

Golden, Colorado, United States

Northwestern University

Chicago, Illinois, United States

Norton Healthcare, Inc

Louisville, Kentucky, United States

William Beaumont Hospital

Royal Oak, Michigan, United States

TRIA Orthopaedic Center Research Institute

Bloomington, Minnesota, United States

Mississippi Sports Medicine and Orthopaedic Center, PLLC

Jackson, Mississippi, United States

Advance Bone and Joint

City of Saint Peters, Missouri, United States

Washington University

St Louis, Missouri, United States

University of Buffalo

Buffalo, New York, United States

Rothman Institute

Philadelphia, Pennsylvania, United States

Intermountain Health

Murray, Utah, United States

Fukui General Hospital

Fukui, Japan

Iwaki City Medical Center

Fukushima, Japan

Yuuai Medical Center

Okinawa, Japan

Kichijoji Minami Hospital

Tokyo, Japan

Kensington Private Hospital

Whangarei, New Zealand

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04984291


Related Trials